A groundbreaking study by Moderna and Merck reveals that a newly developed cancer vaccine is showing promising results in preventing melanoma tumors from recurring in patients. Early findings indicate the vaccine may substantially lower the risk of relapse, marking a potential turning point in immunotherapy for advanced skin cancer. The results, published as part of a large-scale trial, suggest the treatment could offer long-term benefits where previous options have fallen short. If confirmed, this development could reshape how melanoma—a deadly and aggressive form of skin cancer—is treated in the future.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
